Janux Therapeutics Announces Board and Compensation Changes
Ticker: JANX · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1817713
| Field | Detail |
|---|---|
| Company | Janux Therapeutics, Inc. (JANX) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: JANX
TL;DR
Janux Therapeutics filed an 8-K for board and exec comp changes. Watch for details.
AI Summary
On September 18, 2025, Janux Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific details on these arrangements are not provided in this excerpt.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding leadership stability and strategic direction.
Key Players & Entities
- Janux Therapeutics, Inc. (company) — Registrant
- September 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 10955 Vista Sorrento Parkway, Suite 200, San Diego, California 92130 (address) — Principal Executive Offices
- (858) 751-4493 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but the specific names and details of the changes are not provided in this excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to compensatory arrangements for certain officers, but the specific details are not included in this excerpt.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated September 18, 2025.
Where are Janux Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 10955 Vista Sorrento Parkway, Suite 200, San Diego, California 92130.
What is the filing date of this 8-K report?
The 8-K report was filed as of September 19, 2025.
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-09-19 17:06:47
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share JANX Nasdaq Glo
Filing Documents
- janx-20250918.htm (8-K) — 45KB
- 0001193125-25-209259.txt ( ) — 150KB
- janx-20250918.xsd (EX-101.SCH) — 27KB
- janx-20250918_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. JANUX THERAPEUTICS, INC. Date: September 19, 2025 By: /s/ David Campbell, Ph.D. David Campbell, Ph.D. President and Chief Executive Officer